Why the Speed Is the Interesting Part

Monoamine antidepressants raise synaptic serotonin within hours but take four to six weeks to change mood, which told researchers decades ago that the serotonin increase is not itself the therapeutic event. Ketamine inverted the puzzle: Berman and colleagues in 2000, then Zarate and colleagues in 2006, documented antidepressant response within hours. Explaining that speed is what drove the whole glutamate line of research.

• SSRIs raise serotonin quickly but take weeks to work, a long-standing puzzle
• Ketamine response appears within hours in controlled trials
• Speed implies a different mechanism, not a faster version of the same one
• The 2006 Zarate trial is the reference point most later work builds on
• Rapid onset matters clinically when suicidal ideation is present

The Mechanism as Currently Understood

Ketamine blocks NMDA receptors, and the widely accepted account is that this occurs preferentially on inhibitory interneurons, disinhibiting pyramidal cells and producing a glutamate surge. That surge activates AMPA receptors, which engages mTOR signaling and increases BDNF, and the downstream result is synaptogenesis in prefrontal regions where chronic stress and depression produce measurable synaptic loss. Li and colleagues demonstrated the mTOR-dependent synaptogenesis step, which is the part of the story with the firmest experimental support.

• NMDA blockade acts preferentially on inhibitory interneurons
• Disinhibition produces a downstream glutamate surge
• AMPA activation engages mTOR signaling and raises BDNF
• New synaptic connections form in prefrontal regions
• Depression is associated with measurable synaptic loss in those same regions

What Is Genuinely Unsettled

Two open questions matter enough to state. The first is whether NMDA blockade is the essential step at all: other NMDA antagonists have not reliably produced ketamine-like antidepressant effects, which is difficult to reconcile with the simple account. The second is the metabolite question. Hydroxynorketamine appears to carry antidepressant activity in animal models without NMDA blockade and without dissociation, which if it holds in humans would mean the dissociative experience is a side effect rather than the mechanism. Neither question is resolved, and anyone presenting the mechanism as fully understood is overstating it.

• Other NMDA antagonists have not reliably replicated the antidepressant effect
• Hydroxynorketamine shows activity in animal models without NMDA blockade
• Whether dissociation is necessary for benefit remains genuinely open
• Human metabolite data lags well behind the rodent work
• The clinical effect is better established than the explanation for it

What This Means for Sublingual Dosing

Route changes pharmacology in ways worth knowing. Sublingual ketamine has lower and more variable bioavailability than intravenous, and produces relatively more norketamine because more of the dose passes through first-pass metabolism. Whether that shifts the therapeutic profile is not settled, and it is a legitimate reason to prefer infusion in some cases. It is also why sublingual dosing is not simply an intravenous protocol at a different number.

• Sublingual bioavailability is lower and more variable than intravenous
• A greater proportion of metabolites is produced by this route
• Dosing is not a straightforward conversion from infusion protocols
• Onset is slower and the peak is gentler than an infusion
• For some presentations an infusion clinic remains the better referral

The Practical Implication

The synaptogenesis account has one clear clinical consequence: the plasticity window is an opportunity, not the treatment. New connections form more readily for a period after dosing, and what you do during that period influences what gets consolidated. This is the neurobiological reason therapy alongside ketamine outperforms ketamine alone, and it is why we ask about your therapy arrangements rather than treating them as optional.

• The post-session period is when new patterns consolidate most readily
• Therapy during that window has better outcomes than dosing alone
• Sleep and structured reflection in the days after each session matter
• Returning to unchanged circumstances limits what the window can do
• Integration is a clinical step, not an upsell